Профилактическая эффективность рекомбинантного интерферона α-2b в условиях пандемии COVID-19

Понежева, Ж.Б.; Гришаева, А. А.; Маннанова, Ирина; Купченко, А. Н.; Яцышина, С. Б.; Krasnova, S.V.; Малиновская, В В; Акимкин, В. Г.

doi:10.26295/os.2020.29.66.011

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В настоящее время иммунную систему принято разделять на систему врожденного и адаптивного иммунитета [34]. При инфекционных респираторных заболеваниях крайне важно подключение обеих систем к защите организма [35][36][37]. На первом этапе в ответ на внедрение вируса инфицированные клетки начинают производить ранние ИФН -ИФН-α и ИФН-b, представляющие собой активные медиаторы врожденного противовирусного иммунитета.…”

Section: бронхопульмонология и отоларингологияunclassified

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

Zakirova,

Moroz,

Shayapova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Acute respiratory viral infections hold a dominant place in the infectious diseases pattern. There are many drugs that can affect separate arms of the immune response.Aim. To analyze the effectiveness of the systemic use of a combined drug containing interferon-α-2b and a complex immunoglobulin preparation in the treatment of respiratory diseases in frequently ill children.Material and methods. We examined 103 children aged 2-12 years. Upon admission, the children were treated with a combined drug containing interferon a-2b and a complex immunoglobulin preparation (CIP) (Kipferon®) rectally. Children in the control group received standard therapy.Results. Children were admitted to the hospital in the first days of the disease (66.02%), mainly in the moderate form of the disease (96.12%). 81.55% had symptoms of intoxication, catarrhal phenomena and respiratory syndrome. Comparing the time from the onset of the disease when prescribing IFN-α-2b to children, their significantly significant differences were established. Introduction in the early stages of the disease contributes to a faster elimination of all symptoms: fever stopped on average (M ± SD) after 1.76 ± 0.33 and 2.05 ± 0.29 days, respectively, from the moment of admission to the hospital, which was on average 2 days less than in the control group. The transition to a productive cough in the main group occurred on average (M ± SD) after 3.25 ± 0.27 days, in the comparative group - after 5.23 ± 0.31, in the control group - after 8.19 ± 0.42 days. In patients of the main and comparative groups, the length of stay in the hospital was significantly shorter - on average (M ± SD) 8.04 ± 0.81 days than in the control group - 10.56 ± 1.42 days. Hematological parameters returned to normal at an earlier time.Discussion. Rectal route of recombinant IFNi-a2b delivery as suppositories is substantiated with regard to etiopathogenesis and immunology.Conclusion. The article presents the outcomes of the clinical use of Kipferon® as part of the combination therapy and prevention of complications of acute respiratory viral infections in children: reduced duration of intoxication, fever, faster improvement of the auscultatory status of the lungs, improvement of immune status indicators.

show abstract

Section: бронхопульмонология и отоларингологияunclassified

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

Zakirova,

Moroz,

Shayapova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Положительные результаты исследования противовирусной активности IFNα-2b, экстрагированного из готовой лекарственной формы препарата ВИФЕРОН ® (суппозитории ректальные), делают перспективным его применение в клинической практике для профилактики и лечения COVID-19. Сообщается об успешном опыте применения препарата для профилактики среди медицинских работников, контактирующих с больными COVID-19 [1].…”

Section: заключениеunclassified

<i>In vitro</i> antiviral activity of VIFERON® rectal suppositories against SARS-CoV-2

Isakova–Sivak

Stepanova

Rudenko

et al. 2022

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

In 2020–2021, the world was engulfed by the pandemic of a new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus. The low population coverage with vaccination against COVID-19 and the lack of herd immunity result in the need to find an effective and safe etiotropic treatment. Medicinal agents for treatment of COVID-19, approved while preparing this publication, have several limitations related to the conditions of their use and/or population category. In this situation, interferon-containing drugs widely used in Russia and the CIS for prevention and treatment of viral infectious diseases, i.e. ARVI and influenza, may hold promise. This study aims to confirm in vitro antiviral activity against SARS-CoV-2 for the preparation VIFERON® containing recombinant human interferon alpha-2b (IFNα-2b). Materials and methods. Vero CCL-81 cells were infected with hCoV-19/StPetersburg-RII3524VR4/2020 strain of SARS-CoV-2 at doses of 10 TCID50 or 100 TCID50 per well. The suppressive effect of IFN-2b, extracted from VIFERON® in dosage form of rectal suppositories, was evaluated by qRT-PCR at 24 h and 48 h after the infection of cells in two schemes, simulating preventive (24 h before infection) and therapeutic (2 h after infection) use of drugs. Results. IFNα-2b at concentrations of 800, 400, 200, 100 and 50 IU/ml, extracted from rectal suppositories of VIFERON®, showed high biological activity, displayed as inhibition of SARS-CoV-2 strain replication in both infectious doses evaluated either at 24 h or at 48 h after cell infection. The “preventive” vs. “therapeutic” scheme was found to be more effective. In the “preventive” scheme the virus titre decreased by more than 3 lg TCID50 at 24 hours post-infection and by 5–6 lg TCID50 at 48 hours post-infection after administration of 800 IU/ml IFNα-2b. Conclusion. The study results evidence that VIFERON® in dosage form of rectal suppositories may be promising for prevention and treatment of new coronavirus infection in clinical practice.

show abstract

Non-specific prevention of respiratory infections during vaccination against COVID-19

Khasanova,

Soloveva,

Kostinov

et al. 2023

Cytokines and inflammation

View full text Add to dashboard Cite

The novel coronavirus infection (COVID-19) has a suppressive effect on innate immunity, which is a prerequisite for developing strategies to enhance this non-specific link as a preventive measure to protect against other respiratory infections during the ongoing circulation of mutating strains of the SARS-CoV-2 virus. Despite the currently developed and available preventive measures, it has been noted that in persons who have undergone COVID-19, repeated episodes of both coronavirus infection and diseases caused by other pathogens have been recorded. This review analyzes data from the biomedical literature and considers examples of health risks associated with continued infection with pathogens that cause respiratory tract pathologies. It also reflects the ways and approaches of possible preventive measures, the purpose of which is to prevent the development of pathologies of both the respiratory organs and other systems.

show abstract

Профилактическая эффективность рекомбинантного интерферона α-2b в условиях пандемии COVID-19

Cited by 5 publications

References 0 publications

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

<i>In vitro</i> antiviral activity of VIFERON® rectal suppositories against SARS-CoV-2

Non-specific prevention of respiratory infections during vaccination against COVID-19

Contact Info

Product

Resources

About